In many jurisdictions, PRL-8-53 remains unscheduled, meaning it is not a controlled substance, but it is also not approved by the FDA or similar regulatory bodies for medical use. It is primarily handled as a research chemical. Final Thoughts

Preliminary animal studies indicate it may influence serotonin levels, which could impact cognitive processing and mood. Key Findings in Research

The most notable evidence for PRL-8-53 comes from a 1978 human trial. The findings included:

Formally known as Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate , PRL-8-53 is a synthetic compound derived from benzoic acid. It was first synthesized in the 1970s by Dr. Nikolaus Hansl at Creighton University. It was classified as a "hypermnesic" drug—a substance hypothesized to enhance memory beyond baseline levels. How It Works: The Mechanism

While the exact mechanism of action is still being explored, research suggests PRL-8-53 may interact with several key neurotransmitter pathways: